– SWITZERLAND, Muttenz – Opterion Health AG, a Swiss-based life sciences company developing a next-generation, non-glucose-based peritoneal dialysis solution, announced the appointments of Rice Powell and Mark Hahn to its Board of Directors, bringing decades of leadership in renal care, biotechnology, and corporate strategy, reinforcing the company’s commitment to innovation and improving patient outcomes.
About Rice Powell
Rice Powell brings more than 30 years of experience in the global dialysis and healthcare industry. As Chairman and CEO of Fresenius Medical Care, he led the world’s largest provider of dialysis products and services through a decade of strategic transformation and international growth. His leadership was instrumental in expanding access to renal therapies and improving standards of care across continents.
About Mark Hahn
Mark Hahn brings over two decades of financial leadership in the life sciences sector. Currently serving as CFO of Verona Pharma, he has played a central role in fundraising, IPO execution, and scaling operations in both private and public biotech companies. His previous roles include CFO positions at Dova Pharmaceuticals, Cempra, and Athenix, where he consistently delivered financial strategy aligned with corporate growth.
Mark Hahn also works closely with David Ebsworth, Chairman of Opterion Health, at Verona Pharma. Their ongoing collaboration and shared experience navigating complex financial and regulatory environments will be instrumental as Opterion Health advances its clinical and commercial roadmap.
About Opterion Health AG
Opterion Health is developing a novel peritoneal dialysis (PD) solution aimed at revolutionizing the dialysis market. Backed by leading life science investors, the company is headquartered in the Basel area, the pharmaceutical heart of Switzerland, and supported by a strong team of scientists, entrepreneurs, and nephrologists across Europe.
For more: https://opterion.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.